The CDC has expanded its RSV (respiratory syncytial virus) vaccine recommendations to include all adults over 50, broadening the eligibility from the previous recommendation of 60 and older. The change reflects new data showing significant RSV-related hospitalizations in the 50-59 age group.
RSV causes approximately 177,000 hospitalizations and 14,000 deaths annually among older adults in the United States. The virus is often mistaken for a common cold but can progress to pneumonia and respiratory failure in vulnerable populations.
Two approved RSV vaccines, Arexvy (GSK) and Abrysvo (Pfizer), are now recommended for the expanded population. Both showed approximately 80% efficacy against severe RSV disease in clinical trials, with protection lasting at least two seasons.
Insurance coverage has been extended to match the new recommendations, with most plans covering the vaccine with zero copay. The vaccines are available at pharmacies and primary care offices nationwide.
The expanded recommendation is expected to prevent an estimated 25,000 additional hospitalizations annually. Healthcare providers are encouraged to offer RSV vaccination alongside annual flu shots and COVID boosters during fall immunization campaigns.
